At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies and unleash the power of myeloid cells in cancer.
Our proprietary ATAK™ platform is designed to designed to turn myeloid cells against tumors. These engineered cells find, recognize and penetrate tumors. These cells also prime other elements of the immune system, including T cells, thereby reinforcing the anti-tumor immune response, culminating in cancer eradication.
We share your passion for science. Promega is committed to excellence in technologies for cellular therapy programs (e.g., CART cells and T cell receptor modifications) as well as immuno-oncology (e.g., LAG-3, TIM-3, ICOS, CD28, ADCC/ADCP and bi-specific mAbs). All assays are based on bright and sensitive firefly or NanoLuc luciferases. Let’s collaborate.
MaxCyte is a leading provider of cell-engineering platform technologies driving the nextgeneration of cell-based therapies.
MaxCyte has granted 13 strategic platform licenses to leading cellbased therapy developers. Through 2020, MaxCyte has granted licenses for 140+ cell therapy programs, with 100+ licensed for clinical use. Our Flow Electroporation® technology
and next-generation ExPERT® platform enable our partners to accelerate, streamline, and improve the drug development process.
Learn more at www.maxcyte.com